









Markets
/
Stocks
/
nasdaq-rmd
/

Resmed Inc

RMD



View Detailed Chart

253.070USD

+0.800+0.32%

Close 12/15, 16:00（ET）Quotes delayed by 15 min

36.93BMarket Cap

25.79P/E TTM



Resmed Inc

253.070

+0.800+0.32%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

+0.32%

5 Days

+1.21%

1 Month

+3.52%

6 Months

+1.50%

Year to Date

+10.66%

1 Year

+6.10%

View Detailed Chart

TradingKey Stock Score of Resmed Inc

Currency: USD Updated: 2025-12-12

Key Insights

Resmed Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 9/208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 294.23.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Resmed Inc's Score

Industry at a Glance

Industry Ranking

9 / 208

Overall Ranking

65 / 4592

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 21 analysts

Buy

Current Rating

294.230

Target Price

+17.67%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Resmed Inc Highlights

StrengthsRisks

ResMed Inc. is a holding company. The Company, through its subsidiaries, in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. Its segments include Sleep and Breathing Health segment and the Residential Care Software segment. It also operates a Software as a Service (SaaS) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. Its products and solutions are designed to improve patients' quality of life and reduce the impact of chronic disease. Its cloud-based digital health software applications, along with its devices, are designed to provide connected care.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 21.86% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 5.15B.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 22.19%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 22.19%.

Undervalued

The company’s latest PE is 25.71, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 95.81M shares, decreasing 3.84% quarter-over-quarter.

Held by ETHSX

Star Investor ETHSX holds 17.10K shares of this stock.

Resmed Inc News

[IN-DEPTH ANALYSIS] ResMed: The Leader in Sleep Health, Powering Future Investment Growth

The current P/E ratio is 21x, lower than the five-year average of 32x. The target price for fiscal year 2026 is expected to be $295 (with a P/E ratio of 27x).

TradingKeyWed, Jun 4